Ornithine transcarbamoylase deficiency – Diagnostics – Overview of Information and Clinical Research

Understanding how ornithine transcarbamylase deficiency is diagnosed can be life-saving. This rare genetic disorder affects the body’s ability to remove ammonia from the blood, and catching it early through proper testing makes all the difference between preventing brain damage and facing serious complications. From blood tests that reveal elevated ammonia levels to genetic testing that confirms the diagnosis, knowing when and how to seek these evaluations is crucial for anyone who might be affected.

Introduction: Who Should Undergo Diagnostics

Ornithine transcarbamylase deficiency requires prompt diagnostic attention, especially when certain warning signs appear. Newborn boys should be evaluated urgently if they show symptoms such as poor feeding, vomiting, lethargy, or unusual sleepiness within the first few days of life, typically between 24 hours to a few days after birth. These early symptoms often emerge after protein feeding and can rapidly progress to more serious complications if left unaddressed.^[1]

It is advisable to seek diagnostic evaluation for children and adults who experience episodes of unexplained confusion, persistent headaches, nausea, vomiting, or changes in mental status. These symptoms can appear at any age, from infancy through adulthood, and may be triggered by specific situations such as illness, fever, surgery, high protein intake, or periods of stress. Women with a family history of the condition should also consider diagnostic testing, as female carriers can develop symptoms even though they possess two X chromosomes.^[3]^[4]

People with a detailed dietary history showing protein avoidance—meaning they naturally tend to avoid meat and other protein-rich foods—should discuss diagnostic testing with their healthcare provider. This pattern often appears in individuals with undiagnosed ornithine transcarbamylase deficiency, as their bodies instinctively recognize that protein consumption makes them feel unwell.^[5]

⚠️ Important

Anyone experiencing altered mental status, seizures, or loss of consciousness after consuming protein or during illness should receive immediate medical evaluation. High ammonia levels can cause permanent brain damage, and the length of time a person experiences elevated ammonia is directly related to their prognosis. Quick action in seeking diagnostics during these episodes can prevent severe neurological complications or death.^[5]

Family members of individuals diagnosed with ornithine transcarbamylase deficiency should also undergo diagnostic screening, even if they feel completely healthy. Because this condition is inherited in an X-linked pattern, mothers of affected boys are often carriers who may not show obvious symptoms but could still be at risk for hyperammonemic episodes under certain circumstances. Siblings may also be affected or be carriers, making family screening an important preventive measure.^[7]

Diagnostic Methods for Identifying the Disease

The diagnosis of ornithine transcarbamylase deficiency begins with blood testing to measure ammonia levels. When ammonia accumulates in the bloodstream, it reaches toxic concentrations that can be detected through laboratory analysis. Blood ammonia testing is typically one of the first diagnostic steps when a healthcare provider suspects a urea cycle disorder, which is a class of genetic diseases that includes ornithine transcarbamylase deficiency. The urea cycle is a series of chemical reactions in the liver that normally converts toxic ammonia into urea, which can then be safely eliminated through urine.^[8]^[15]

In addition to measuring ammonia levels, doctors will evaluate amino acid levels in the blood. Individuals with ornithine transcarbamylase deficiency typically show elevated levels of glutamine and alanine, two amino acids that accumulate as a result of high ammonia. Glutamine functions as a temporary storage site for excess ammonia in the body. Interestingly, these amino acid elevations may appear before ammonia levels rise significantly and before symptoms begin, making them useful early warning signs of metabolic decompensation in someone with the condition.^[14]

Another important test measures citrulline levels in the blood. Citrulline is a substance produced during the normal urea cycle through the action of the ornithine transcarbamylase enzyme. When this enzyme is deficient or missing, citrulline production decreases. Therefore, individuals with ornithine transcarbamylase deficiency typically have low or low-to-normal citrulline levels, which helps distinguish this condition from other urea cycle disorders that may show different patterns.^[7]

Urine testing plays a crucial role in diagnosing ornithine transcarbamylase deficiency. Specifically, doctors look for elevated levels of orotic acid in the urine. Orotic acid is produced when carbamoyl phosphate—a substance that would normally be used in the urea cycle—accumulates and is diverted into another metabolic pathway. A markedly abnormal increase in orotic acid excretion, particularly levels at or above 20 micromoles per millimole of creatinine in a random urine sample, strongly suggests ornithine transcarbamylase deficiency. Sometimes an allopurinol challenge test is performed, which involves giving the patient a medication called allopurinol and then measuring orotic acid levels afterward to see if they increase further.^[7]^[13]

Genetic testing provides definitive confirmation of ornithine transcarbamylase deficiency. This testing looks for changes or mutations in the OTC gene, which provides instructions for making the ornithine transcarbamylase enzyme. Researchers have identified at least 400 different DNA changes that can cause this condition. In male patients, finding a hemizygous pathogenic variant—meaning a disease-causing change in their single copy of the OTC gene—establishes the diagnosis. In female patients, finding a heterozygous pathogenic variant—a disease-causing change in one of their two copies of the gene—confirms the diagnosis.^[4]^[7]

However, genetic testing has limitations. Studies have documented cases where routine DNA sequencing methods did not identify any disease-causing variants, even though the person clearly had ornithine transcarbamylase deficiency based on their symptoms and other test results. In fact, about one in five cases do not show a detectable DNA change with current testing methods. This highlights why clinical judgment and biochemical testing remain essential, and why doctors should not rule out the diagnosis simply because genetic tests come back negative.^[2]^[4]

Liver function tests provide additional diagnostic information. These blood tests measure various enzymes and substances produced by the liver to assess how well it is working. Some individuals with ornithine transcarbamylase deficiency may show signs of progressive liver damage over time, making these tests important for monitoring the condition.^[1]

In some cases, a liver biopsy may be performed. This procedure involves taking a small sample of liver tissue to directly measure ornithine transcarbamylase enzyme activity. Decreased enzyme activity in liver tissue, combined with appropriate clinical and laboratory findings, can establish the diagnosis even when genetic testing is inconclusive. However, liver biopsy is an invasive procedure and is not always necessary if other diagnostic evidence is sufficient.^[7]

Brain imaging studies, such as magnetic resonance imaging (MRI), may be performed when patients present with neurological symptoms. These scans can reveal characteristic patterns of brain injury associated with high ammonia levels. For example, MRI images may show specific areas of damage in regions such as the insular cortex, frontal lobes, or cingulate gyrus. These imaging findings can support the diagnosis and help doctors understand the extent of any brain damage that may have occurred during hyperammonemic episodes.^[13]

⚠️ Important

Diagnosis requires combining multiple pieces of information rather than relying on any single test. A doctor must consider the patient’s symptoms, medical history, family history, and results from blood tests, urine tests, and potentially genetic testing to reach a confident diagnosis. The importance of clinical and biochemical suspicion cannot be overstated, particularly in cases where genetic testing fails to reveal a clear answer.^[2]

Distinguishing ornithine transcarbamylase deficiency from other conditions is an important part of the diagnostic process. Several other disorders can also cause elevated ammonia levels, including other types of urea cycle disorders, severe liver disease, certain infections, and toxic exposures. Specific patterns in amino acid levels, orotic acid excretion, and citrulline levels help doctors differentiate ornithine transcarbamylase deficiency from these other possibilities. For instance, other urea cycle disorders may show different amino acid patterns or high rather than low citrulline levels.^[2]

The diagnostic approach may differ slightly depending on when symptoms first appear. For newborns presenting in the first few days of life with severe symptoms, rapid testing for ammonia, amino acids, and orotic acid is essential to begin life-saving treatment as quickly as possible. For individuals with later-onset disease who may have milder symptoms that come and go, diagnostic testing might occur during a symptomatic episode or might involve challenge testing when the person is feeling well to see if abnormalities can be detected.^[7]

Diagnostics for Clinical Trial Qualification

Clinical trials investigating new treatments for ornithine transcarbamylase deficiency require specific diagnostic criteria to ensure that enrolled patients truly have the condition and meet the study’s requirements. These qualification criteria typically include confirmation of the diagnosis through genetic testing showing a pathogenic variant in the OTC gene, documented evidence of elevated ammonia levels at some point in the patient’s medical history, and biochemical findings consistent with the disorder.^[7]

Baseline ammonia levels are usually measured as part of clinical trial enrollment to establish each participant’s starting point before any experimental treatment begins. This allows researchers to determine whether the investigational therapy successfully reduces ammonia levels compared to the participant’s pre-treatment status. Regular monitoring of ammonia levels throughout the trial helps assess the treatment’s effectiveness and safety.^[14]

Plasma amino acid analysis is another standard requirement for clinical trial qualification. This testing establishes baseline levels of key amino acids including glutamine, alanine, and citrulline. Changes in these amino acid patterns during the trial can provide important information about how well an experimental treatment is working to improve metabolic function. Since glutamine and alanine serve as markers that may rise before clinical symptoms appear, tracking these values helps researchers detect potential problems early.^[14]

Genetic confirmation through DNA testing is typically mandatory for clinical trial enrollment. Research protocols generally require documented evidence of a pathogenic or likely pathogenic variant in the OTC gene. However, some trials may accept participants who have a clinical and biochemical diagnosis of ornithine transcarbamylase deficiency even without an identified genetic variant, particularly given that approximately 20 percent of cases do not show detectable mutations with standard testing methods.^[2]^[4]

Liver function tests, including measurement of liver enzymes and assessment of overall liver health, are standard components of clinical trial screening. These tests help researchers determine whether participants have significant liver damage that might affect their ability to tolerate experimental treatments or that might influence how their bodies respond to therapy. Some trials may exclude participants with advanced liver disease, while others might specifically target this population.^[1]

Neurological assessments may be required for clinical trial qualification to document any existing cognitive or neurological impairment resulting from previous hyperammonemic episodes. These evaluations establish a baseline that allows researchers to determine whether an experimental treatment prevents further neurological decline or potentially improves function. Testing might include neuropsychological assessments to measure memory, attention, learning, and executive function.^[7]

Dietary history and protein intake records are often collected as part of clinical trial enrollment. Researchers need to understand each participant’s current dietary restrictions and protein tolerance to properly interpret study results. If an experimental treatment allows participants to increase their protein intake without developing high ammonia levels, this would represent an important benefit that improves quality of life.^[10]

Documentation of previous hyperammonemic crises, including their frequency, severity, and triggers, provides important background information for clinical trials. This history helps researchers understand each participant’s disease severity and allows them to determine whether an investigational treatment reduces the number or severity of hyperammonemic episodes compared to the participant’s pre-treatment pattern.^[7]

Regular monitoring during clinical trials typically includes repeated measurement of ammonia levels, amino acid profiles, liver function tests, and urinary orotic acid excretion at scheduled intervals. These repeated tests allow researchers to track changes over time and assess whether the experimental treatment is having the desired metabolic effects. Participants may need to undergo testing weekly, monthly, or at other predetermined intervals depending on the specific trial protocol.^[14]

Prognosis and Survival Rate

Prognosis

The outlook for individuals with ornithine transcarbamylase deficiency varies considerably depending on several factors, including the severity of the enzyme deficiency, the age when symptoms first appear, and how quickly the condition is diagnosed and treated. People with severe neonatal-onset disease, particularly males who show symptoms in the first few days of life, face the most serious prognosis. These infants can easily become hyperammonemic again despite appropriate treatment, and they typically require liver transplantation to improve their quality of life and long-term survival.^[7]

The prognosis is well correlated with the length of the hyperammonemic period rather than the degree of hyperammonemia itself. This means that the duration of time a person’s brain is exposed to elevated ammonia levels matters more than how high the ammonia level peaks. Prompt recognition and rapid treatment of hyperammonemic episodes are crucial for preventing permanent brain damage. Even individuals with late-onset forms of the disease remain at risk for life-threatening hyperammonemic episodes when exposed to appropriate stressors such as illness, surgery, or high protein intake.^[5]^[7]

Neuropsychological complications affect many individuals with ornithine transcarbamylase deficiency. Typical challenges include developmental delay, learning disabilities, intellectual disability, attention-deficit/hyperactivity disorder, and problems with executive function—the mental skills that help with planning, organization, and self-control. These complications can occur even in people whose condition is generally well-managed, particularly if they experienced hyperammonemic episodes that damaged their brain before diagnosis or during acute crises.^[7]

Liver transplantation is considered curative for ornithine transcarbamylase deficiency because it provides a healthy liver with normal ornithine transcarbamylase enzyme activity. After successful transplantation, patients can stop dietary protein restrictions and ammonia scavenging medications. However, transplantation will not reverse any pre-existing neurological injury that occurred before the procedure. For this reason, early liver transplantation, typically by six months of age, is recommended for individuals with severe neonatal-onset disease. People with late-onset disease and heterozygous female carriers may also undergo liver transplantation if it is deemed more favorable than medical management alone. This group of patients has a favorable long-term outlook following transplantation.^[10]^[15]

Thanks to medical advances, particularly within the last 25 years, ornithine transcarbamylase deficiency is now extremely treatable. People diagnosed and managed appropriately can live meaningful lives with proper dietary management, medications that help remove ammonia from the body, and careful monitoring to prevent hyperammonemic crises. The key to a good prognosis is early diagnosis, strict adherence to treatment recommendations, and rapid intervention whenever symptoms suggest rising ammonia levels.^[4]

Survival Rate

The survival rate for ornithine transcarbamylase deficiency depends significantly on disease severity and how quickly it is recognized and treated. For infants with severe neonatal-onset disease, approximately 50 percent die despite medical intervention, reflecting the extremely serious nature of hyperammonemic crisis in newborns. These deaths typically occur when the condition is not recognized quickly enough or when hyperammonemia causes irreversible brain damage before treatment can be initiated.^[5]

Survival rates are considerably better for individuals with later-onset forms of the disease, particularly when the diagnosis is established before a severe hyperammonemic crisis occurs. People whose condition is identified through family screening or through investigation of mild symptoms can begin preventive treatment before experiencing life-threatening complications, which substantially improves their survival prospects. Careful medical management with dietary protein restriction and ammonia-scavenging medications allows many individuals with ornithine transcarbamylase deficiency to avoid the severe metabolic crises that threaten survival.^[7]

For those who undergo liver transplantation, survival rates are favorable. This procedure essentially cures the metabolic defect by providing a liver with normal enzyme function, eliminating the risk of future hyperammonemic crises related to ornithine transcarbamylase deficiency. The success of transplantation in this population has made it an increasingly important treatment option, particularly for individuals with severe disease who experience frequent metabolic crises despite optimal medical management.^[15]

#1 Clinical Trials Search in Europe